MXPA04003526A - Composicion y metodo para el tratamiento de la diabetes. - Google Patents

Composicion y metodo para el tratamiento de la diabetes.

Info

Publication number
MXPA04003526A
MXPA04003526A MXPA04003526A MXPA04003526A MXPA04003526A MX PA04003526 A MXPA04003526 A MX PA04003526A MX PA04003526 A MXPA04003526 A MX PA04003526A MX PA04003526 A MXPA04003526 A MX PA04003526A MX PA04003526 A MXPA04003526 A MX PA04003526A
Authority
MX
Mexico
Prior art keywords
composition
treating diabetes
ingap
formulation
formulations
Prior art date
Application number
MXPA04003526A
Other languages
English (en)
Inventor
Scott Mohrland
Original Assignee
Gmp Endotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gmp Endotherapeutics Inc filed Critical Gmp Endotherapeutics Inc
Publication of MXPA04003526A publication Critical patent/MXPA04003526A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/474—Pancreatic thread protein; Reg protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4733—Acute pancreatitis-associated protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invencion comprende regimenes de dosificacion y formulaciones de proteinas (INGAP) y el peptido INGAP asociados con la neogenesis de las celulas de los islotes. La formulacion expuesta en la presente ha demostrado tener una estabilidad aceptable como composicion farmaceutica. Ademas, dicha formulacion es capaz de regenerar los islotes funcionales.
MXPA04003526A 2001-10-16 2002-10-15 Composicion y metodo para el tratamiento de la diabetes. MXPA04003526A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32933001P 2001-10-16 2001-10-16
PCT/US2002/032904 WO2003033808A2 (en) 2001-10-16 2002-10-15 Composition and method for treating diabetes

Publications (1)

Publication Number Publication Date
MXPA04003526A true MXPA04003526A (es) 2004-07-22

Family

ID=23284879

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04003526A MXPA04003526A (es) 2001-10-16 2002-10-15 Composicion y metodo para el tratamiento de la diabetes.

Country Status (20)

Country Link
US (2) US20040132644A1 (es)
EP (1) EP1435995A2 (es)
JP (1) JP2005506362A (es)
KR (1) KR20050036865A (es)
CN (1) CN1723034A (es)
BR (1) BR0213291A (es)
CA (1) CA2463769A1 (es)
CO (2) CO5570658A2 (es)
CZ (1) CZ2004479A3 (es)
HU (1) HUP0401612A3 (es)
IL (1) IL161073A0 (es)
MA (1) MA27503A1 (es)
MX (1) MXPA04003526A (es)
NO (1) NO20042012L (es)
PE (1) PE20030608A1 (es)
PL (1) PL370069A1 (es)
RU (1) RU2004114865A (es)
SK (1) SK1702004A3 (es)
WO (1) WO2003033808A2 (es)
ZA (1) ZA200402261B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003275853A1 (en) * 2002-10-24 2004-05-13 Mcgill University Use of ingap for reversing diabetes
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
WO2006096565A2 (en) * 2005-03-04 2006-09-14 Curedm Inc. Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
CA2726759C (en) * 2005-05-25 2016-02-16 Curedm Group Holdings, Llc Human proislet peptide, derivatives and analogs thereof, and methods of using same
EP1840573A1 (en) * 2006-03-27 2007-10-03 Institut Pasteur Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections
US8785400B2 (en) * 2006-11-22 2014-07-22 Curedm Group Holdings, Llc Methods and compositions relating to islet cell neogenesis
EP2570431A3 (en) * 2007-08-30 2013-05-01 CureDM Group Holdings, LLC Compositions and methods of using proislet peptides and analogs thereof
WO2014052611A1 (en) * 2012-09-27 2014-04-03 Levetan Claresa Generation of new pancreatic beta cells
CN104045702A (zh) * 2013-03-15 2014-09-17 深圳君圣泰生物技术有限公司 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物
US20160039877A1 (en) 2013-03-15 2016-02-11 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof
CN104045699A (zh) * 2013-03-15 2014-09-17 深圳君圣泰生物技术有限公司 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物
CN104045698B (zh) * 2013-03-15 2019-04-16 深圳君圣泰生物技术有限公司 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物
CN103305457B (zh) * 2013-06-06 2015-07-08 浙江省医学科学院 一种体外扩增胰岛β细胞的方法
US20160039876A1 (en) * 2014-03-28 2016-02-11 Claresa Levetan Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide
WO2017152861A1 (en) * 2016-03-10 2017-09-14 Shenzhen Hightide Biopharmaceutical, Ltd. Conjugates of islet neogenesis peptides and analogs, and methods thereof
US20210196646A1 (en) * 2018-08-15 2021-07-01 Wake Forest University Health Sciences Improved formulations for pancreatic islet encapsulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US127624A (en) * 1872-06-04 Improvement in apparatus for elevating water
US4658957A (en) * 1985-01-28 1987-04-21 Abbott Laboratories Utility tray
US6106840A (en) * 1988-06-23 2000-08-22 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
JP4111539B2 (ja) * 1995-02-22 2008-07-02 イースタン・ヴァージニア・メディカル・スクール・オブ・ザ・メディカル・カレッジ・オブ・ハンプトン・ローズ 膵島新生に関与するｉｎｇａｐタンパク質
US5834590A (en) * 1995-02-22 1998-11-10 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Ingap protein involved in pancreatic islet neogenesis
EP0910571B1 (en) * 1996-05-03 2005-07-20 Abbott Laboratories Novel antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis
US6090577A (en) * 1997-05-22 2000-07-18 Incyte Pharmaceuticals, Inc. Disease associated acidic protein
US6986994B2 (en) * 2001-01-09 2006-01-17 Gmp Endotherapeutics, Inc. INGAP displacement assays

Also Published As

Publication number Publication date
IL161073A0 (en) 2004-08-31
SK1702004A3 (sk) 2005-03-04
US20080171704A1 (en) 2008-07-17
RU2004114865A (ru) 2005-05-27
BR0213291A (pt) 2004-10-26
PL370069A1 (en) 2005-05-16
CN1723034A (zh) 2006-01-18
CO5570658A2 (es) 2005-10-31
KR20050036865A (ko) 2005-04-20
CO5590933A2 (es) 2005-12-30
EP1435995A2 (en) 2004-07-14
CA2463769A1 (en) 2003-04-24
ZA200402261B (en) 2004-09-28
JP2005506362A (ja) 2005-03-03
HUP0401612A2 (hu) 2004-12-28
CZ2004479A3 (cs) 2005-01-12
WO2003033808A2 (en) 2003-04-24
MA27503A1 (fr) 2005-09-01
PE20030608A1 (es) 2003-08-26
US20040132644A1 (en) 2004-07-08
WO2003033808A3 (en) 2003-09-18
HUP0401612A3 (en) 2006-04-28
NO20042012L (no) 2004-07-16

Similar Documents

Publication Publication Date Title
MXPA04003526A (es) Composicion y metodo para el tratamiento de la diabetes.
PT1412384E (pt) Formulação estável de glp-1 modificado
MXPA03000442A (es) Una formulacion medicinal en aerosol.
IL145430A0 (en) N-cyanomethyl amides, processes for the preparation thereof and pharmaceutical compositions containing the same
NO965012L (no) Farmasöytisk preparat som omfatter glukagon
DE69912952D1 (en) Cyclosporine
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
WO2002074247A3 (en) Pharmaceutical formulations for sustained release
TW200510306A (en) Novel hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them
NO20002605L (no) Sferoider, fremstillingsmetode og farmasøytiske sammensetninger
HK1042710A1 (en) Covalently bridged insulin dymers
WO2003028758A1 (fr) Nouvelle methode d'induction de lymphocytes t specifiques d'un antigene
WO1999059609A3 (en) Use of hmg proteins for the preparation of medicaments having cytotoxic activity
ES2173638T3 (es) Esferoides que contienen tiagabina, procedimiento de fabricacion y composiciones farmaceuticas.
GEP20063972B (en) Streptogramin derivatives, preparation and compositions containing them
TW200505436A (en) Modified release pharmaceutical compositions and the processes for preparing them
AU2003255355A1 (en) Progesterone receptor modulators having an increased antigonadotropic activity for use in female fertility testing and hormone replacement therapy
DK1538162T3 (da) Sammensætninger til ændring af slimsekretion
HUP9901303A2 (hu) Gyógyszerkészítmény autoimmun betegségek kezelésére
NZ331083A (en) Pharmaceutical preparations of cilansetron stabilized against racemization
DK0989994T3 (da) Streptograminderivater, deres fremstilling og præparater, der indeholder dem
SE9904132D0 (sv) Pharmaceutical composition for treatment of diarrhea
HUP0000812A2 (hu) Myelin bázikus fehérje peptid-fragmentumai az azokat tartalmazó gyógyszerkészítmények és felhasználásuk a sclerosis multiplex kezelésére
IL160160A0 (en) SUBSTITUTED 5,6,6a, 11b-TETRAHYDRO-7-OXA-5-AZA-BENZO[c]FLUORENE-6-CARBOXYLIC ACID DERIVATIVES SERVING AS NMDA ANTAGONISTS
WO2003040316A3 (en) Selective elimination of cd52+ cells and uses thereof